Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACTU Actuate Therapeutics	$5.76 -8.0%	$8.21	$5.50 ▼ $11.99	$113.01M	N/A	60,930 shs	87,198 shs
IGC IGC Pharma	$0.36 +9.5%	$0.32	$0.25 ▼ $0.49	$26.62M	1.45	902,172 shs	214,616 shs
KRRO Korro Bio	$13.67 -1.2%	$13.38	$10.29 ▼ $98.00	$128.37M	2.43	109,000 shs	99,678 shs
TARA Protara Therapeutics	$3.08 -1.9%	$3.12	$1.60 ▼ $10.48	$118.83M	1.35	800,826 shs	123,405 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACTU Actuate Therapeutics	0.00%	-6.19%	-23.10%	-28.00%	+575,999,900.00%
IGC IGC Pharma	0.00%	-6.05%	+18.60%	+27.05%	+35,699,900.00%
KRRO Korro Bio	0.00%	+7.55%	+9.71%	-1.65%	-71.73%
TARA Protara Therapeutics	0.00%	+0.98%	+3.36%	-21.03%	+33.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACTU Actuate Therapeutics	2.0772 of 5 stars	3.5	0.0	1.1	3.3	0.0
IGC IGC Pharma	1.4227 of 5 stars	3.5	0.0	0.6	1.7	0.0
KRRO Korro Bio	1.3447 of 5 stars	3.6	1.0	0.6	0.0	0.6
TARA Protara Therapeutics	1.4067 of 5 stars	3.6	1.0	1.1	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACTU Actuate Therapeutics	3.00	Buy	$20.50	255.90% Upside
IGC IGC Pharma	3.00	Buy	$3.88	985.43% Upside
KRRO Korro Bio	3.29	Buy	$102.43	649.29% Upside
TARA Protara Therapeutics	3.14	Buy	$20.50	565.58% Upside

Current Analyst Ratings Breakdown

Latest IGC, KRRO, TARA, and ACTU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/3/2025	ACTU Actuate Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$20.00
5/22/2025	TARA Protara Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$21.00
5/13/2025	KRRO Korro Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
5/13/2025	KRRO Korro Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$155.00 ➝ $90.00
5/8/2025	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$115.00 ➝ $100.00
4/29/2025	KRRO Korro Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	KRRO Korro Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$74.00
4/28/2025	TARA Protara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/22/2025	ACTU Actuate Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	$0.01 per share	N/A
IGC IGC Pharma	$1.27M	22.38	N/A	N/A	$0.08 per share	4.46
KRRO Korro Bio	$2.27M	56.55	N/A	N/A	$17.12 per share	0.80
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	$4.77 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACTU Actuate Therapeutics	-$27.28M	N/A	0.00	∞	N/A	N/A	N/A	-339.73%	N/A
IGC IGC Pharma	-$13M	-$0.08	N/A	N/A	N/A	-714.16%	-122.44%	-88.40%	N/A
KRRO Korro Bio	-$83.58M	-$9.44	N/A	N/A	N/A	N/A	-51.64%	-37.94%	8/12/2025 (Estimated)
TARA Protara Therapeutics	-$44.60M	-$1.72	N/A	N/A	N/A	N/A	-36.37%	-33.29%	8/5/2025 (Estimated)

Latest IGC, KRRO, TARA, and ACTU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	KRRO Korro Bio	-$2.54	N/A	N/A	N/A	$0.41 million	N/A
8/5/2025	Q2 2025	TARA Protara Therapeutics	-$0.43	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	ACTU Actuate Therapeutics	-$0.26	-$0.32	-$0.06	-$0.32	N/A	N/A
5/8/2025	Q1 2025	TARA Protara Therapeutics	-$0.47	-$0.29	+$0.18	-$0.29	N/A	N/A
5/7/2025	Q1 2025	KRRO Korro Bio	-$2.60	-$2.49	+$0.11	-$2.49	$0.13 million	$2.55 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A
IGC IGC Pharma	N/A	N/A	N/A	N/A	N/A
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACTU Actuate Therapeutics	N/A	0.46	0.46
IGC IGC Pharma	0.02	1.15	0.98
KRRO Korro Bio	N/A	9.41	9.41
TARA Protara Therapeutics	N/A	18.03	18.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACTU Actuate Therapeutics	N/A
IGC IGC Pharma	3.87%
KRRO Korro Bio	13.18%
TARA Protara Therapeutics	38.13%

Insider Ownership

Company	Insider Ownership
ACTU Actuate Therapeutics	69.34%
IGC IGC Pharma	31.48%
KRRO Korro Bio	4.60%
TARA Protara Therapeutics	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACTU Actuate Therapeutics	10	19.62 million	6.02 million	N/A
IGC IGC Pharma	61	79.69 million	54.60 million	N/A
KRRO Korro Bio	70	9.39 million	8.96 million	No Data
TARA Protara Therapeutics	30	38.58 million	35.34 million	Optionable

IGC, KRRO, TARA, and ACTU Headlines

Recent News About These Companies

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - The Manila Times

July 2, 2025 | manilatimes.netM

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - Morningstar

July 2, 2025 | morningstar.comM

Protara Therapeutics, Inc. Added to Russell 3000® Index, Enhancing Visibility in Financial Community - Nasdaq

July 2, 2025 | nasdaq.com

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 1, 2025 | globenewswire.com

Protara Therapeutics, Inc. Added to Russell 3000® Index, Enhancing Visibility in Financial Community

June 30, 2025 | quiverquant.comQ

Protara Therapeutics Announces Addition to the Russell 3000® Index

June 30, 2025 | globenewswire.com

Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Rating of "Buy" by Brokerages

June 30, 2025 | marketbeat.com

Protara Therapeutics, Inc. (TARA) - Yahoo Finance

June 26, 2025 | finance.yahoo.com

RAPT Therapeutics Appoints Scott Braunstein, M.D. and Ashley Dombkowski, Ph.D. to Board of Directors

June 23, 2025 | quiverquant.comQ

Protara Therapeutics: Marching On To A Hopefully Eventful Back Half Of 2025

June 14, 2025 | seekingalpha.com

Chutes & Ladders—Protara gears up for next steps with commercial pro

June 7, 2025 | fiercebiotech.comF

The Escalator: Digitas Health, Bristol Myers Squibb, Inizio Evoke and more

June 4, 2025 | mmm-online.comM

Protara Therapeutics names new Chief Commercial Officer

June 4, 2025 | investing.com

Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer

June 2, 2025 | globenewswire.com

Jones Trading Initiates Coverage of Protara Therapeutics (TARA) with Buy Recommendation

May 23, 2025 | msn.com

Richard Levy Spends US$64k On Protara Therapeutics Stock

May 22, 2025 | finance.yahoo.com

With 73% ownership, Protara Therapeutics, Inc. (NASDAQ:TARA) boasts of strong institutional backing

May 16, 2025 | finance.yahoo.com

Protara Therapeutics to Participate in Upcoming Investor Conferences

May 13, 2025 | globenewswire.com

Protara Therapeutics Reports Q1 2025 Financial Results

May 10, 2025 | tipranks.com

Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025 | globenewswire.com

How Protara Therapeutics Reflects Shifts Among Nasdaq Companies by Market Cap

May 3, 2025 | kalkinemedia.comK

New MarketBeat Followers Over Time

Media Sentiment Over Time

IGC, KRRO, TARA, and ACTU Company Descriptions

Actuate Therapeutics NASDAQ:ACTU

$5.76 -0.50 (-7.99%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$5.90 +0.14 (+2.43%)

As of 07/18/2025 05:39 PM Eastern

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

IGC Pharma NYSEMKT:IGC

$0.36 +0.03 (+9.48%)

Closing price 07/18/2025 03:58 PM Eastern

Extended Trading

$0.34 -0.02 (-5.04%)

As of 07/18/2025 08:00 PM Eastern

IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

Korro Bio NASDAQ:KRRO

$13.67 -0.16 (-1.16%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$13.72 +0.05 (+0.40%)

As of 07/18/2025 04:04 PM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Protara Therapeutics NASDAQ:TARA

$3.08 -0.06 (-1.91%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$3.08 0.00 (0.00%)

As of 07/18/2025 05:26 PM Eastern

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time